Demographic and clinical characteristics of 58 patients with acquired TTP
| Demographic characteristics . | Acquired TTP (n = 58) . | Normal values . |
|---|---|---|
| Male/female | 14/44 | |
| Age, median (range), y | 45 (18-79) | |
| Age at first episode, median (range), y | 43 (18-79) | |
| Clinical features at acute presentation, n (%)∗ | ||
| First TTP event | 42 (72%) | |
| Systemic symptoms | 45 (78%) | |
| Neurological alterations | 27 (47%) | |
| Cardiac alterations | 8 (14%) | |
| Renal alterations | 13 (22%) | |
| Bleeding | 41 (71%) | |
| Laboratory features at acute presentation, median (range) | ||
| Platelet count, 109/L | 16 (4-106) | 150-450 |
| Hb, g/dL | 8.8 (5.2-14.8) | 13.0-16.0 |
| LDH, IU/L | 1136 (278-7243) | 105-333 |
| Creatinine, mg/dL | 0.90 (0.40-6.20) | 0.60-1.20 |
| Complement activation in different clinical conditions, median (range), sC5b-9, ng/mL | ||
| All conditions, n = 58 | 351 (78-1106)∗ | 120 (68-202) |
| Systemic symptoms, n = 45 | 365 (124-1106) | |
| No systemic symptoms, n = 13 | 330 (78-660) | |
| Neurological alterations, n = 31 | 339 (124-1051) | |
| No neurological alterations, n = 27 | 338 (78-1106) | |
| Cardiac alterations, n = 8 | 384 (253-1051) | |
| No cardiac alterations, n = 50 | 345 (78-1106) | |
| Renal alterations, n = 13 | 460 (221-1051)† | |
| No renal alterations, n = 45 | 322 (78-1106) | |
| Bleeding, n = 41 | 331 (78-1106) | |
| No bleeding, n = 17 | 381 (123-856) |
| Demographic characteristics . | Acquired TTP (n = 58) . | Normal values . |
|---|---|---|
| Male/female | 14/44 | |
| Age, median (range), y | 45 (18-79) | |
| Age at first episode, median (range), y | 43 (18-79) | |
| Clinical features at acute presentation, n (%)∗ | ||
| First TTP event | 42 (72%) | |
| Systemic symptoms | 45 (78%) | |
| Neurological alterations | 27 (47%) | |
| Cardiac alterations | 8 (14%) | |
| Renal alterations | 13 (22%) | |
| Bleeding | 41 (71%) | |
| Laboratory features at acute presentation, median (range) | ||
| Platelet count, 109/L | 16 (4-106) | 150-450 |
| Hb, g/dL | 8.8 (5.2-14.8) | 13.0-16.0 |
| LDH, IU/L | 1136 (278-7243) | 105-333 |
| Creatinine, mg/dL | 0.90 (0.40-6.20) | 0.60-1.20 |
| Complement activation in different clinical conditions, median (range), sC5b-9, ng/mL | ||
| All conditions, n = 58 | 351 (78-1106)∗ | 120 (68-202) |
| Systemic symptoms, n = 45 | 365 (124-1106) | |
| No systemic symptoms, n = 13 | 330 (78-660) | |
| Neurological alterations, n = 31 | 339 (124-1051) | |
| No neurological alterations, n = 27 | 338 (78-1106) | |
| Cardiac alterations, n = 8 | 384 (253-1051) | |
| No cardiac alterations, n = 50 | 345 (78-1106) | |
| Renal alterations, n = 13 | 460 (221-1051)† | |
| No renal alterations, n = 45 | 322 (78-1106) | |
| Bleeding, n = 41 | 331 (78-1106) | |
| No bleeding, n = 17 | 381 (123-856) |
Clinical signs and symptoms were categorized as follows: systemic (fatigue, fever, abdominal pain, headache, jaundice, and vomiting), neurological (stroke, seizures, coma, personality change, focal neurological signs, and transitory ischemic attack), cardiac (acute coronary syndrome and electrocardiographic ischemic abnormalities), renal (an increase in serum creatinine ≥0.3 mg/dL within 48 hours, ≥50% within 7 days, or a urine output of <0.5 mL/kg per hour for >6 hours, per the Kidney Disease Improving Global Outcomes guidelines), and bleeding (hematuria, meno-metrorrhagia, mucosal bleeding, gastrointestinal tract bleeding, ecchymosis, and purpura).
Hb, hemoglobin; LDH, lactate dehydrogenase.
sC5b-9 in all the conditions vs healthy controls P = .0001.
sC5b-9 in renal alterations vs no renal alterations P = .01.